For the quarter ended June 2026, Elevance Health (ELV) reported revenue of $49.83 billion, up 0.8% over the same period last year. EPS came in at $7.45, compared to $8.84 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $48.45 billion, representing a surprise of +2.85%. The company delivered an EPS surprise of +20.55%, with the consensus EPS estimate being $6.18.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Elevance Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Total Medical Membership: 44.95 million compared to the 44.82 million average estimate based on 17 analysts. Medical Membership - Medicaid: 8.36 million versus the 17-analyst average estimate of 8.23 million. Medical Membership - Medicare - Medicare Supplement: 893 thousand versus the 17-analyst average estimate of 878.19 thousand. Medical Membership - Commercial Risk-Based - Employer Group Risk-Based: 3.42 million versus the 17-analyst average estimate of 3.39 million. Revenues- Net investment income: $704 million versus the 17-analyst average estimate of $446.85 million. The reported number represents a year-over-year change of +44.9%. Revenues- Service fees: $2.28 billion versus $2.24 billion estimated by 17 analysts on average. Compared to the year-ago quarter, this number represents a +8.3% change. Revenues- Premiums: $41.28 billion versus $39.9 billion estimated by 17 analysts on average. Compared to the year-ago quarter, this number represents a 0% change. Revenues- Product revenue: $6.26 billion versus the 17-analyst average estimate of $6.32 billion. The reported number represents a year-over-year change of +3.7%. Total operating revenue- Corporate & Other: $6 million versus $148.14 million estimated by 16 analysts on average. Compared to the year-ago quarter, this number represents a -97.4% change. Total operating revenue- Carelon Services: $7.98 billion versus the 16-analyst average estimate of $7.41 billion. The reported number represents a year-over-year change of +7.2%. Total operating revenue- CarelonRx: $11.25 billion versus $10.95 billion estimated by 16 analysts on average. Compared to the year-ago quarter, this number represents a +5.7% change. Total operating revenue- Health Benefits: $42.72 billion versus the 16-analyst average estimate of $41.15 billion. The reported number represents a year-over-year change of +2.7%.View all Key Company Metrics for Elevance Health here>>>
Shares of Elevance Health have returned +7.3% over the past month versus the Zacks S&P 500 composite's +1.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Elevance Health, Inc. (ELV): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).